| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2022 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PROTHENA CORP PLC | 19 | Q2 2019 | 37.7% |
| ALKERMES PLC | 18 | Q1 2019 | 28.0% |
| THERAVANCE BIOPHARMA INC | 17 | Q3 2019 | 71.3% |
| BIOGEN INC | 12 | Q1 2019 | 9.8% |
| ABBVIE INC | 9 | Q3 2017 | 33.9% |
| NORTHWEST BIOTHERAPEUTICS INC | 9 | Q4 2016 | 12.7% |
| REYNOLDS AMERICAN INC | 7 | Q3 2016 | 45.9% |
| EVOFEM BIOSCIENCES INC | 7 | Q3 2019 | 20.3% |
| AUTOLUS THERAPEUTICS PLC | 6 | Q3 2019 | 33.9% |
| GILEAD SCIENCES INC | 6 | Q4 2017 | 7.6% |
View Woodford Investment Management Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Evofem Biosciences, Inc.Sold out | February 04, 2020 | 0 | 0.0% |
| Nightstar Therapeutics plcSold out | February 04, 2020 | 0 | 0.0% |
| Theravance Biopharma, Inc. | November 08, 2019 | 429,770 | 0.8% |
| Autolus Therapeutics plc | October 09, 2019 | 2,095,127 | 4.7% |
| NuCana plc | September 09, 2019 | 1,538,000 | 4.8% |
| Prothena Corp plcSold out | September 09, 2019 | 0 | 0.0% |
| NORTHWEST BIOTHERAPEUTICS INC | February 14, 2019 | 24,815,028 | 4.8% |
View Woodford Investment Management Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2020-02-04 |
| SC 13G/A | 2020-02-04 |
| 13F-HR | 2020-01-27 |
| 13F-HR/A | 2019-11-12 |
| 13F-HR | 2019-11-08 |
| SC 13G/A | 2019-11-08 |
| SC 13G/A | 2019-11-08 |
| SC 13G/A | 2019-10-09 |
| SC 13G/A | 2019-09-09 |
| SC 13G/A | 2019-09-09 |
View Woodford Investment Management Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.